These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 20052538)

  • 21. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
    Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
    Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.
    Henderson SL; Teft WA; Kim RB
    BMC Cancer; 2016 May; 16():304. PubMed ID: 27169677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced preclinical efficacy of tamoxifen developed as alginate-cysteine/disulfide bond reduced albumin nanoparticles.
    Martínez A; Muñiz E; Iglesias I; Teijón JM; Blanco MD
    Int J Pharm; 2012 Oct; 436(1-2):574-81. PubMed ID: 22850290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
    Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
    Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?
    Brauch H; Jordan VC
    Eur J Cancer; 2009 Sep; 45(13):2274-83. PubMed ID: 19592233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualization of tamoxifen treatment for breast carcinoma.
    Binkhorst L; van Gelder T; Mathijssen RH
    Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.
    Teft WA; Gong IY; Dingle B; Potvin K; Younus J; Vandenberg TA; Brackstone M; Perera FE; Choi YH; Zou G; Legan RM; Tirona RG; Kim RB
    Breast Cancer Res Treat; 2013 May; 139(1):95-105. PubMed ID: 23580071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
    Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
    Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents.
    Biegon A; Brewster M; Degani H; Pop E; Somjen D; Kaye AM
    Cancer Res; 1996 Oct; 56(19):4328-31. PubMed ID: 8813117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lignan-rich sesame seed negates the tumor-inhibitory effect of tamoxifen but maintains bone health in a postmenopausal athymic mouse model with estrogen-responsive breast tumors.
    Sacco SM; Chen J; Power KA; Ward WE; Thompson LU
    Menopause; 2008; 15(1):171-9. PubMed ID: 17545920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of sesame seed and tamoxifen on tumor growth and bone health in athymic mice.
    Sacco SM; Power KA; Chen J; Ward WE; Thompson LU
    Exp Biol Med (Maywood); 2007 Jun; 232(6):754-61. PubMed ID: 17526767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
    Lu WJ; Desta Z; Flockhart DA
    Breast Cancer Res Treat; 2012 Jan; 131(2):473-81. PubMed ID: 21390495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug-Drug Interaction with Antidepressants.
    MacLeod AK; McLaughlin LA; Henderson CJ; Wolf CR
    Drug Metab Dispos; 2017 Jan; 45(1):17-22. PubMed ID: 27756789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of baicalein on the pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by baicalein.
    Li C; Kim M; Choi H; Choi J
    Arch Pharm Res; 2011 Nov; 34(11):1965-72. PubMed ID: 22139696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.